Background & Aims: In patients with non-alcoholic fatty liver disease (NAFLD), liver
| BACKG ROU N D
Non-alcoholic fatty liver disease (NAFLD) accounts for the most increasing cause of chronic liver disease, hepatocellular carcinoma and of end-stage liver disease leading to liver transplantation. 1, 2 Cohort studies demonstrated that among NAFLD populations, those with non-alcoholic steatohepatitis (NASH) have a higher risk of fibrosis progression, and that the presence of severe liver fibrosis is the main driver of hepatic and extra-hepatic prognosis. 2, 3 Even if liver biopsy is considered the diagnostic gold standard, the availability of non-invasive markers to be used in NAFLD patients to predict NASH and/or severity of fibrosis represents a relevant medical need. 4 To date, the diagnosis of NASH in clinical practice by using non-invasive scores is difficult because of the lack of wellperforming and well-validated tools. 5 Furthermore, novel-proposed NASH blood biomarkers, such as CK18-Asp396 fragments, showed low sensitivity for NASH detection. 5, 6 Different scores are available for the non-invasive assessment of fibrosis (eg 'aspartate aminotransferase (AST)-to-platelet ratio index' (APRI) and the 'four factors-based fibrosis index' (FIB-4); some of them are very easy to use and implement in clinical practice even if there are limitations such as false-positive results and high uncertainty areas. 3, 7 When looking at imaging devices, liver stiffness measurement (LSM) through transient elastography (FibroScan) is a widely diffused tool, even if its accuracy can be influenced by obesity and severity of steatosis. 7, 8 Circulating RNAs in plasma or serum have been attracting exponential attention as novel non-invasive diagnostic biomarkers of several kinds of diseases. Body fluid RNAs, including long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs), have many of the essential characteristics of good biomarkers, for example: (i) they are non-invasive accessible; (ii) their levels can easily be determined by basic molecular biology methods, first of all real-time PCR; (iii) they are remarkably stable in spite of the high amounts of endogenous ribonuclease in body fluids such as serum and plasma. [9] [10] [11] Several studies have highlighted the stability of lncRNAs and mRNAs, also under various experimental and pre-analytical oppressive conditions, including multiple freeze-thaw cycles, prolonged incubation at room temperature (up to 24h), exogenous RNAse treatments, time delay in processing of blood after venipuncture, low/high pH. 10, [12] [13] [14] [15] The stability of lncRNAs and mRNAs in different body fluids against endogenous ribonuclease degradation may be provided by vesicles encapsulation and/or RNA binding protein association and also their highly stable secondary structures. 10, 11, 16, 17 Two very recent studies reported the aberrant expression of long non-coding RNAs (lncRNAs) in liver tissue of NAFL/NASH patients and in mice models of NAFLD. 18, 19 Furthermore, increasing trend ranging from CTRL to oleate:palmitate or only palmitate-treated cells both at intracellular and extracellular level, while BNIP3L was up-regulated only at extracellular level. UBE2V1, RP11-128N14.5, TGFB2/TGFB2-OT1 and HBA2 up-regulation was also observed at histological level. UBE2V1, RP11-128N14.5, BNIP3L and TGFB2/ TGFB2-OT1 correlated with histological/biochemical data. Combinations of TGFB2/ TGFB2-OT1 + Fibrosis Index based on the four factors (FIB-4) showed an Area
Under the Curve (AUC) of 0.891 (P = 3.00E-06) or TGFB2/TGFB2-OT1 + Fibroscan (AUC = 0.892, P = 2.00E-06) improved the detection of F = 3-4 with respect to F = 0-2 fibrosis stages.
Conclusions:
We identified specific serum coding/non-coding RNA profiles in severe and mild NAFLD patients that possibly mirror the molecular mechanisms underlying NAFLD progression towards NASH/fibrosis. TGFB2/TGFB2-OT1 detection improves FIB-4/Fibroscan diagnostic performance for advanced fibrosis discrimination.
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LAY SUMMARY
• Liver biopsy still remains the gold standard for NAFLD diagnosis confirmation, distinction between simple steatosis and NASH, and fibrosis staging. No study has been performed regarding the circulating lncRNA and mRNA signatures as biomarkers in NAFLD patient serum.
• Our study suggests the use of coding and non-coding RNA as non-invasive biomarkers of NAFLD and fibrosis severity. Combination of coding/non-coding RNA expression levels and clinical data could be conveniently applied as a diagnostic tool for non-invasive screening of NAFLD patients according to disease severity.
experimental evidence is beginning to characterize the role of specific lncRNAs in the pathogenesis of liver fibrosis 20 and several metabolic functions, such as free fatty acid β-oxidation, lipogenesis and insulin secretion. 21 Numerous studies performed high-throughput analysis of mRNAs in liver tissues from NAFLD patients or in vivo animal models, which allowed the identification of several pathways associated with disease progression. [22] [23] [24] [25] [26] To date, no study has been performed on circulating mRNA and lncRNA signatures in sera from NAFLD patients. Therefore, the main aim of this work was to analyse the whole transcriptome profile in serum samples of NAFLD biopsydiagnosed patients to identify novel non-invasive biomarkers which are able to identify NAFLD patients with NASH and/or advanced fibrosis.
| MATERIAL S AND ME THODS

| Study subjects
This study involved two subject cohorts, namely: a first study co- 
| RNA E X TR AC TI ON
We performed RNA extraction from serum samples of study cohorts, 
| MICROARR AY ANALYS IS
| COMPUTATIONAL ANALYS IS
| IN VITRO CELL CULTURE E XPERIMENTS
Human hepatoblastoma cell line HepG2 was cultured as previously reported. 27 To obtain in vitro models of NAFL or NASH, HepG2 at 75% confluence were exposed to a mixture of oleate/palmitate or only palmitate at a final fatty acid concentration of 0.5 mM for 48 h respectively.
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| S ING LE RE AL-TIME P CR A SSAYS
Validation of candidate coding/non-coding RNAs both in an independent internal cohort of 88 study subjects (63 NAFLD and 
| STATISTICAL ANALYSIS
| RE SULTS
| WHOLE TRANSCRIPTOME ANALYSIS
In order to identify novel potential biomarker signatures associated with NAFLD spectrum, we performed a whole transcriptome analysis in sera from four mild NAFLD patients (NAS ≤ 4; F = 0), 
| PATHWAY ANALYS IS OF DIFFERENTIALLY E XPRE SS ED TR ANSCRIP TS
To explore the potential functions of deregulated transcripts, 
| VALIDATI ON BY qP CR s
In order to confirm microarray data, we analysed the expression of characteristics of each cohort subjects are reported in Table 1 . We selected the following transcripts: HBA2, UBE2V1, BNIP3L coding RNAs, RP11-128N14.5 lncRNA and TGFB2/TGFB2-OT1 coding/ non-coding RNA. We chose these transcripts because: (i) they presented high levels of fluorescence microarray signals; (ii) they presented a low P-value in severe NAFLD vs mild NAFLD comparison (P ≤ 0.02); (iii) they were potentially linked to oxidative stress, inflammatory, apoptotic, authophagy or fibrogenic pathways according to literature data. 29, 30, 35 We also selected one ncRNA GenBank ID: AC020558.4 ('AceView' database gene name: 'sherveebu') as a down-regulated control molecule. 
| VALIDATED TR AN SCRIP TS ARE A SSO CIATED WITH CLINI C AL MARK ER S AND HIS TOLOG IC AL SCORE S
We analysed whether -ΔCt values of validated transcripts were associated through a linear regression relationship both with the metabolic syndrome and liver damage-associated routine biochemical markers as with histological markers used in clinical practice to diagnose and stage NAFLD and fibrosis severity (Table   S2 ). Table S2 .
| E XPRE SS I ON ANALYS IS OF LIVER TISSUE S AND IN VITRO MODEL S
In order to further investigate the possible link between validated transcripts and cellular/molecular mechanisms associated with disease evolution, we evaluated whether RNA deregulation observed in serum of NAFLD patients was also present in liver tissue of NAFLD patients and in in vitro models of NAFL and NASH, both at intracellular and extracellular levels. Total RNA was extracted from liver bi- used an in vitro model that we already used in a previous work.
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HepG2 cells were exposed for 48 h to a mixture of oleate:palmitate (OA:PA) or only to palmitate (PA), to simulate simple steatosis or NASH respectively.
As shown in Figure Figure 4B ). Furthermore, it is important to note that HBA2
was undetectable in HepG2 culture medium.
| RECEIVER OPER ATING CHAR AC TERIS TIC S CURVE ANALYS IS
By performing ROC curve analysis, we investigated, the di- with AST or ALT in both cohorts decreased its AUC: 0.5 P = 1.
| D ISCUSS I ON
In this multiphase case-control study, we performed an initial and TGFB2/TGFB2-OT1 (P = 3.10E-02); Kleiner ballooning score correlated with UBE2V1 (P = 4.50E-02), BNIP3L (P = 2.60E-02), RP11-128N14.5 (P = 1.20E-02); Kleiner fibrosis score correlated with BNIP3L (P = 3.60E-02), RP11-128N14.5 (P = 3.70E-02) and TGFB2/TGFB2-OT1 (P = 1.60E-02). The statistical correlation with histological scores of disease severity and fibrosis stages suggests that analysed transcripts could be potentially associated with NASH and hepatic fibrogenesis molecular features.
Explaining the relationship between RNA extracellular expression and affected tissues is a difficult challenge. We tried to respond to this question by verifying whether RNA deregulation in patients could be somehow mirrored in liver tissue of NAFLD subjects and into in vitro models of NAFLD disease, both at intracellular and extracellular levels.
María José Gómez-Lechón et al, 36 and also our research group, A link between haemoglobin levels and NASH already exists.
Akyuz et al reported that increased serum haemoglobin is the only independent predictor of both NASH and hepatic fibrosis in NAFLD patients with BMI < 25 kg/m 2 . 37 Trak-Smayra and colleagues performed a proteomic study in a cohort of obese patients in the presence or absence of liver lesions: they observed an increase of free haemoglobin subunits ranging from obese patients without liver lesion to those with simple steatosis and then to NASH, which returned to normal values after weight loss. 38 Whether increased free serum haemoglobin subunits is owing to the increased hemolysis or increased gene and protein expression occurring in the affected liver, needs to be elucidated. In support of the first hypothesis, it has been reported that oxidative stress induces an increased erythrocyte susceptibility to haemolysis in animal models of NASH 30 and in obese subjects. 39 In support of the second hypothesis, Liu et al reported an increased expression of HBA1 and HBB in liver There are no published data on the association between the RAP2A coding gene and NAFLD spectrum; however, it has been reported that in hepatocellular carcinoma, RAP2A regulates MAP4K4, which leads to JNK and NF-κB signalling activation which are the members of common molecular pathways of NASH pathogenesis.
TGF-β is a homodimer that exists in three different isoforms (-β1, -β2 and -β3) in mammals and all TGF-β ligands act through the same receptor signalling systems. It has been widely demonstrated that, in the liver, TGF-β signalling is involved in the fibrogenic response through hepatic stellate cell activation. Furthermore, it has been reported that TGF-β signalling in hepatocytes contributes to hepatocyte death and lipid accumulation that promote the development of NASH. 42 In real-time validation experiments, we used primers able to amplify both mRNA encoding for TGFB2 and lncRNA TGFB2-Overlapping Transcript 1, a newly discovered lncRNA deriving from the 3'-UTR of TGFB2. We found that levels of TGFB2/TGFB2-OT1
were highly increased in serum samples of patients with a NAS ≥ 5
and fibrosis F = 3-4.
Several studies have highlighted the role of TGFB2-OT1 in the regulation of autophagy, apoptotic, inflammatory and fibrogenic pathways, all known to be involved in NAFLD progression. 43 It has been reported that TGFB2-OT1 is involved in the negative regulation of apoptosis and positive regulation of autophagy and inflammation in vascular endothelial cells. 31, 44 Long Xiang Tu and colleagues reported the up-regulation of TGFB2-OT1 in fibroblasts derived from hypertrophic scars, suggesting its involvement in excessive proliferation of fibroblasts and accumulation of extracellular matrix. 45 As concerns TGFB2, its pro-fibrogenic role and/or its increased gene or protein expression has been reported in lens fibrosis, kidney fibrosis, cardiac fibrosis and liver fibrosis.
46
Several studies reported the involvement of BNIP3L in the regulation of pathways associated with NASH pathogenesis, specifically, apoptosis, necrosis, autophagy and fibrosis. Several studies supported BNIP3L involvement in apoptosis and necrosis of cardiomyocyte in heart diseases. 47 HIF1b-dependent BNIP3L increased gene and protein expression has been reported in primary cultured hepatocytes exposed to ethanol and in mice models of alcohol-induced liver injury and steatosis. 48 Although these data support the potential activation of this pathway in liver steatosis, we did not observe its activation in liver biopsies and in in vitro model at intracellular level. Concerning the pro-fibrogenic role of BNIP3L, Weili Liu and colleagues reported that the expression of BNIP3L is increased in cardiac fibrosis.
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Although the major limitation of our study is the small sample size, our results may contribute to increase the understanding of NAFLD physiopathology. Our qPCR results, or other results deriving from microarray analysis or from similar studies, need to be validated in larger patient cohorts with a clearer stratification according to NAS (NAS ≤ 3 vs NAS ≥ 5). Serum RNAs should be analysed in in vivo animal models in which genetic and environmental confounding effects should be minimized. Finally, intracellular
RNAs should be assessed in liver biopsies of larger patient cohort.
Notwithstanding these limitations, our data contribute to expand the knowledge on molecular mechanisms associated with NAFLD pathophysiology. Moreover, they could provide the evidence for identification of novel biomarkers as future possible alternatives to liver biopsy.
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